FDA OKs Coherus' Version of Abbvie's Humira, Best-Selling Drug in U.S.

 Coherus BioSciences  (CHRS) - Get Coherus BioSciences, Inc. Report said the U.S. Food and Drug Administration had approved its treatment for a variety of psoriasis-related conditions.

The Redwood City, Calif., company said in a statement that the product, Yusimry, treats plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, Crohn’s disease, and ulcerative colitis.

The company said that approval for the treatment was based on data that demonstrated the biosimilarity of Yusimry to AbbVie's  (ABBV) - Get AbbVie, Inc. Report Humira. 

The FDA defines biosimilars as having "no clinically meaningful differences in safety, purity or potency (safety and effectiveness) compared to the reference product."

https://www.thestreet.com/investing/coherus-stock-rises-fda-approves-biosimilar-to-abbvie-humira